FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890135040> ?p ?o ?g. }

• W2890135040 endingPage "e0203054" @default.
• W2890135040 startingPage "e0203054" @default.
• W2890135040 abstract "Background Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in humans. The primary aim of this study was to determine the difference between four-months of treatment with GR-MD-02 or placebo in liver inflammation and fibrosis as measured by iron-corrected T1 (cT1) mapping, a non-invasive magnetic resonance imaging (MRI) biomarker that correlates with the extent of hepatic fibro-inflammatory disease. The secondary aims were to determine change in liver stiffness as measured by magnetic resonance elastography (MRE) and shear-wave ultrasonic elastography (LSM), and to explore test-retest repeatability of the three biomarkers. Materials and methods Thirty subjects (13 females, 46–71 years) with NASH and advanced fibrosis were recruited. Subjects were randomized to receive 8 mg.kg-1 GR-MD-02 (via IV infusion) or placebo, administered biweekly over a 16-week period. Therapeutic efficacy was examined using cT1, MRE, and LSM. Statistical analyses on group differences in the biomarkers were performed using robust ANCOVA models adjusting for baseline measurement and additional covariates. Results There was no significant difference in cT1 (p = 0.16) between GR-MD-02 and placebo groups following a 16-week intervention. There was also no significant difference in liver stiffness, measured by MRE (p = 0.80) or LSM (p = 0.63), between groups. Examination of repeatability of the cT1, MRE and LSM revealed coefficient of variations of 3.1%, 11% and 40% respectively. Conclusions 8 mg.kg-1 of GR-MD-02 had no significant effect on non-invasive biomarkers of liver inflammation or fibrosis over a 4-month period. Histological confirmation was not available in this study. The high reproducibility of the primary outcome measure suggests that cT1 could be utilized for monitoring longitudinal change in patients with NASH." @default.
• W2890135040 created "2018-09-27" @default.
• W2890135040 creator A5009209158 @default.
• W2890135040 creator A5030568693 @default.
• W2890135040 creator A5042580299 @default.
• W2890135040 creator A5060274343 @default.
• W2890135040 creator A5060316115 @default.
• W2890135040 creator A5070949973 @default.
• W2890135040 creator A5075647936 @default.
• W2890135040 creator A5076713788 @default.
• W2890135040 creator A5086355131 @default.
• W2890135040 creator A5091625375 @default.
• W2890135040 date "2018-09-07" @default.
• W2890135040 modified "2023-10-12" @default.
• W2890135040 title "Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial" @default.
• W2890135040 cites W1926691574 @default.
• W2890135040 cites W1963682935 @default.
• W2890135040 cites W1963683487 @default.
• W2890135040 cites W1963966669 @default.
• W2890135040 cites W1967657836 @default.
• W2890135040 cites W1967989660 @default.
• W2890135040 cites W1968441132 @default.
• W2890135040 cites W1972974730 @default.
• W2890135040 cites W1989525615 @default.
• W2890135040 cites W1999376895 @default.
• W2890135040 cites W2003518626 @default.
• W2890135040 cites W2006766845 @default.
• W2890135040 cites W2059251195 @default.
• W2890135040 cites W2067691975 @default.
• W2890135040 cites W2067740038 @default.
• W2890135040 cites W2086719465 @default.
• W2890135040 cites W2123549954 @default.
• W2890135040 cites W2138306815 @default.
• W2890135040 cites W2141016294 @default.
• W2890135040 cites W2150691023 @default.
• W2890135040 cites W2153299395 @default.
• W2890135040 cites W2157636987 @default.
• W2890135040 cites W2433376106 @default.
• W2890135040 cites W2466151179 @default.
• W2890135040 cites W2491991204 @default.
• W2890135040 cites W2534481205 @default.
• W2890135040 cites W2535633630 @default.
• W2890135040 cites W2573487838 @default.
• W2890135040 cites W2772079645 @default.
• W2890135040 cites W2802380055 @default.
• W2890135040 cites W2808157877 @default.
• W2890135040 cites W600147071 @default.
• W2890135040 doi "https://doi.org/10.1371/journal.pone.0203054" @default.
• W2890135040 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6128474" @default.
• W2890135040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30192782" @default.
• W2890135040 hasPublicationYear "2018" @default.
• W2890135040 type Work @default.
• W2890135040 sameAs 2890135040 @default.
• W2890135040 citedByCount "53" @default.
• W2890135040 countsByYear W28901350402019 @default.
• W2890135040 countsByYear W28901350402020 @default.
• W2890135040 countsByYear W28901350402021 @default.
• W2890135040 countsByYear W28901350402022 @default.
• W2890135040 countsByYear W28901350402023 @default.
• W2890135040 crossrefType "journal-article" @default.
• W2890135040 hasAuthorship W2890135040A5009209158 @default.
• W2890135040 hasAuthorship W2890135040A5030568693 @default.
• W2890135040 hasAuthorship W2890135040A5042580299 @default.
• W2890135040 hasAuthorship W2890135040A5060274343 @default.
• W2890135040 hasAuthorship W2890135040A5060316115 @default.
• W2890135040 hasAuthorship W2890135040A5070949973 @default.
• W2890135040 hasAuthorship W2890135040A5075647936 @default.
• W2890135040 hasAuthorship W2890135040A5076713788 @default.
• W2890135040 hasAuthorship W2890135040A5086355131 @default.
• W2890135040 hasAuthorship W2890135040A5091625375 @default.
• W2890135040 hasBestOaLocation W28901350401 @default.
• W2890135040 hasConcept C126322002 @default.
• W2890135040 hasConcept C142724271 @default.
• W2890135040 hasConcept C168563851 @default.
• W2890135040 hasConcept C174348530 @default.
• W2890135040 hasConcept C2780559512 @default.
• W2890135040 hasConcept C2994217296 @default.
• W2890135040 hasConcept C31258907 @default.
• W2890135040 hasConcept C41008148 @default.
• W2890135040 hasConcept C535046627 @default.
• W2890135040 hasConcept C60644358 @default.
• W2890135040 hasConcept C71924100 @default.
• W2890135040 hasConcept C86803240 @default.
• W2890135040 hasConceptScore W2890135040C126322002 @default.
• W2890135040 hasConceptScore W2890135040C142724271 @default.
• W2890135040 hasConceptScore W2890135040C168563851 @default.
• W2890135040 hasConceptScore W2890135040C174348530 @default.
• W2890135040 hasConceptScore W2890135040C2780559512 @default.
• W2890135040 hasConceptScore W2890135040C2994217296 @default.
• W2890135040 hasConceptScore W2890135040C31258907 @default.
• W2890135040 hasConceptScore W2890135040C41008148 @default.
• W2890135040 hasConceptScore W2890135040C535046627 @default.
• W2890135040 hasConceptScore W2890135040C60644358 @default.
• W2890135040 hasConceptScore W2890135040C71924100 @default.
• W2890135040 hasConceptScore W2890135040C86803240 @default.
• W2890135040 hasIssue "9" @default.
• W2890135040 hasLocation W28901350401 @default.
• W2890135040 hasLocation W28901350402 @default.

• next